MDT-AP-0712
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 38.04
- os_event
- false
- age_years
- 0.33
- sex
- F
- new_clusters
- S3
- umap1_2d
- -1.316624762
- umap2_2d
- -7.593892523
- umap1_3d
- -2.445816878
- umap2_3d
- -2.53048837
- umap3_3d
- 5.380440317
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.390
- PANCREAS_BETA_CELLS+0.380
- APICAL_SURFACE+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- ESTROGEN_RESPONSE_LATE+0.310
- KRAS_SIGNALING_DN+0.310
- INFLAMMATORY_RESPONSE+0.240
- COAGULATION+0.220
- XENOBIOTIC_METABOLISM+0.220
- COMPLEMENT+0.210
Top 10 suppressed
- PROTEIN_SECRETION-0.360
- TGF_BETA_SIGNALING-0.360
- MITOTIC_SPINDLE-0.330
- MYC_TARGETS_V2-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- HEME_METABOLISM-0.290
- PI3K_AKT_MTOR_SIGNALING-0.220
- MTORC1_SIGNALING-0.160
- UV_RESPONSE_DN-0.150
- WNT_BETA_CATENIN_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2153 | Med | Medulloblastoma | 0.823 |
| 2 | MDT-AP-2385 | Med | Medulloblastoma | 0.757 |
| 3 | MDT-AP-0327 | Med | Medulloblastoma | 0.756 |
| 4 | MDT-AP-2299 | Med | Medulloblastoma | 0.739 |
| 5 | TCGA-A7-A56D-01A-11R-A27Q-07 | — | B | 0.738 |
| 6 | MDT-AP-0809 | Med | Medulloblastoma | 0.732 |
| 7 | SRR1313163 | — | D | 0.719 |
| 8 | SRR5088877 | — | — | 0.716 |
| 9 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.698 |
| 10 | MDT-AP-2372 | Med | Medulloblastoma | 0.698 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |